specificity. The high degree of selective targeting seen in the study
provides additional evidence of bavituximab's therapeutic potential.
Bavituximab Anti-Viral Program: During the third quarter, the company
continued to advance its bavituximab HCV program and presented positive
data at a key liver disease meeting.
-- Added The Johns Hopkins Hospital and a private clinic in Orange
County, California as additional clinical study sites for the HCV/HIV
-- Presented final results from the Phase I multiple dose HCV trial at
the prestigious Annual Meeting of the American Association for the
Study of Liver Disease that showed bavituximab was well tolerated and
demonstrated encouraging signs of anti-viral activity.
Cotara(R) Glioblastoma Program: Peregrine continued to advance the
Cotara brain cancer program.
-- Added additional study sites and continued patient dosing and
follow-up in the Cotara Phase II study in patients with glioblastoma
multiforme, the most deadly form of brain cancer. Eight sites are now
open for patient enrollment.
-- Added an additional site, the Barrow Neurological Institute (BNI) in
Phoenix, Arizona, to the ongoing Cotara dosimetry and dose
confirmation clinical study. BNI also participated in a previous
Cotara Phase II clinical trial.
-- Announced positive results from the first cohort of patients treated
in the Cotara dosimetry trial and from the initial patients treated in
the Cotara Phase II trial. Cotara appeared safe and well tolerated
with no dose-limiting adverse events, with continuing patients being
monitored for overall survival. Several patients in these studies
have lived longer than the six-month expected median survival time for
this patient po
|SOURCE Peregrine Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved